Biotechnology company BioCryst Pharmaceuticals Inc. said Wednesday a flu drug candidate failed a midstage clinical trial, and suggested that the trial design may have been flawed. Shares plummeted in after-hours trading nearly 40 percent.
Internet
Original post by Todd Wallack, Globe Staff
